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Abstract
Mycoplasma hyopneumoniae is the cause of enzootic pneumonia in pigs, a chronic respiratory disease associated
with significant economic losses to swine producers worldwide. The molecular pathogenesis of infection is poorly
understood due to the lack of genetic tools to allow manipulation of the organism and more generally for the
Mycoplasma genus. The objective of this study was to develop a system for generating random transposon
insertion mutants in M. hyopneumoniae that could prove a powerful tool in enabling the pathogenesis of infection
to be unraveled. A novel delivery vector was constructed containing a hyperactive C9 mutant of the Himar1
transposase along with a mini transposon containing the tetracycline resistance cassette, tetM. M. hyopneumoniae
strain 232 was electroporated with the construct and tetM-expressing transformants selected on agar containing
tetracycline. Individual transformants contained single transposon insertions that were stable upon serial passages
in broth medium. The insertion sites of 44 individual transformants were determined and confirmed disruption of
several M. hyopneumoniae genes. A large pool of over 10 000 mutants was generated that should allow saturation
of the M. hyopneumoniae strain 232 genome. This is the first time that transposon mutagenesis has been
demonstrated in this important pathogen and could be generally applied for other Mycoplasma species that are
intractable to genetic manipulation. The ability to generate random mutant libraries is a powerful tool in the further
study of the pathogenesis of this important swine pathogen.
Introduction
Belonging to the class Mollicutes, mycoplasmas are char-
acterised by their lack of a cell wall and small genome
size, and are considered to be the smallest free-living
self-replicating organisms and as such are of considerable
interest in synthetic biology [1]. Respiratory disease is a
major problem facing swine producers and Mycoplasma
hyopneumoniae, the cause of enzootic pneumonia (EP), is
a swine-specific mycoplasma of global prevalence that is
one of the leading causes of disease [2,3]. EP is charac-
terised by a chronic non-productive cough that is most
evident during the growing and fattening stages of pro-
duction, although all ages of animal may be affected [4].
Mortality rates are usually low, but morbidity may be
high with associated economic losses due to increased
medication costs, lower growth rates and lower feed
conversion efficiencies [2]. The pathogenesis of EP in-
volves entry of M. hyopneumoniae into the respiratory
tract by inhalation, largely from nose-to-nose contact
with other pigs [2], and colonisation of the ciliated epi-
thelial cells of the trachea, bronchi and bronchioles [5,6].
Adherence of the organism to the epithelium causes
ciliostasis and loss of cilia, thereby preventing effective
clearance of debris, pathogens and mucus from the airways
[7]. Additionally, M. hyopneumoniae may cause direct cell
damage by production of cytotoxic metabolites such as
hydrogen peroxide [8]. The chronic nature of infection may
result from modulation of the host immune response by
M. hyopneumoniae [2,9] and possibly by variable expres-
sion of bacterial surface antigens, enabling the organism
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to evade effective clearance [10]. M. hyopneumoniae infec-
tion can be associated with and exacerbated by co-infection
with other viral pathogens such as Porcine Reproductive
and Respiratory Syndrome Virus (PRRSV) and Porcine
Circovirus type 2 [2], and with upper respiratory tract bac-
teria such as Actinobacillus pleuropneumoniae, Streptococcus
suis, Haemophilus parasuis and Pasteurella multocida [2].
Commercial M. hyopneumoniae vaccines are in widespread
use in the pig industry where they are reported to lessen
the economic effects of the disease by reducing clinical
signs and lung lesions and by improving performance
parameters [3,11,12]. However, current vaccines are not
completely effective and do not prevent colonisation of
the respiratory tract with M. hyopneumoniae or eliminate
infection from the herd [13].
Central to the design of more effective vaccines is
an understanding of the pathogenesis of EP. Despite
the availability of whole genome sequences of several
M. hyopneumoniae strains and the small genome size,
the functions of most of the protein coding sequences are
still unclear. The chronic nature of M. hyopneumoniae
infection implies a complicated relationship between the
pathogen and the host that is poorly understood. The small
genome size of M. hyopneumoniae offers an appealing op-
portunity to understand the molecular basis of disease for-
mation, and to unravel the interplay between the host and
the pathogen. Traditionally the exploration of gene function
in a bacterium is investigated through the generation of
random insertional mutants by transposon mutagenesis.
Typically for other Mycoplasmas, the Tn4001 transposon
derived from Staphylococcus aureus [14] has been utilised
[15-19]. As reviewed by Halbedel and Stülke [20], a mini
Tn4001 transposon is used containing an antimicrobial
resistance cassette flanked by inverted repeat sequences.
The mini transposon and transposase enzyme are delivered
into the organism by transformation and expression of the
resistance cassette enables selection of mutated organisms.
Insertions in essential genes result in lethality but many
transformants have mutations in genes that are not ne-
cessary for growth in vitro, but may encode for particu-
lar pathogenicity determinants that are necessary for
growth, survival, invasion or disease in the animal. Such
mutants could be exploited in a number of different as-
says, including in vivo screening of mutants using the
powerful technique of signature tagged mutagenesis
[21]. Through the screening of large numbers of random
mutants in vivo, mutants that are attenuated in vivo can
be identified. Such mutants may encode for virulence
factors and may be useful in the identification of live
attenuated vaccine candidates.
Recently we described the first successful transform-
ation of M. hyopneumoniae strain 232 using an artificial
self-replicating oriC plasmid system [22]. This system
allowed us to optimise a set of transformation conditions,
antimicrobial selection cassettes and promoter sequences
for M. hyopneumoniae. In this study, the results of that
work have been used further to develop a transposon mu-
tagenesis system for M. hyopneumoniae. A key feature of
this system is the use of a Himar1 transposon, belonging
to the Mariner family of transposons. Insertion occurs
at any TA dinucleotide [23] offering an excellent po-
tential for complete coverage of the AT-rich genome of
M. hyopneumoniae. We describe the development of this
system and its use in generating a large pool of several
thousand M. hyopneumoniae mutants. This is a major ad-
vancement in the study of this important swine pathogen
and potentially other Mycoplasmas.
Materials and methods
Plasmid construction
PCR was performed using a Phusion High Fidelity kit
(NEB Ltd, Hitchin, UK) according to the manufacturer’s
instructions. Sequences of oligonucleotides used in the
study are shown in Table 1. To construct pTn4001-RVC1
(Figure 1A), the 2293 base pair (bp) tetM gene of the plas-
mid pSRT2 [24] was amplified by PCR (primers TetM1
and TetM2) and cloned into the XbaI and PstI restric-
tion sites of the pMiniTn4001PsPuro plasmid [25].
Mariner transposon plasmids were constructed from
the plasmid pMiniHimar1BSC1 (Figure 1B) [26]. To con-
struct pMHWT-2, firstly the 2293 bp tetM gene in pSRT2
[24] was amplified by PCR (primers TetM3 and TetM4)
and used to replace the puromycin N-acetyl-transferase
(pac) gene of pMiniHimar1BSC1 using the MluI and SbfI
restriction sites (Figure 1C). pMiniHimar1BSC1 contains
the Himar1 transposase gene downstream of the native
promoter sequence from the Tn4001 transposase. To
produce plasmid pMHWT-1 (Figure 1D), the 1050 bp
Himar1 transposase gene minus the Tn4001 promoter
sequence was PCR-amplified from pMiniHimar1BSC1
(primers Tpn1 and Tpn2), introducing an XhoI cut site
at the 3’ end and NdeI and NcoI restriction sites at the
5’ end. This PCR product was cloned into NdeI and
XhoI sites of pMHWT-2, replacing the Himar1 gene
and Tn4001 promoter sequence, and introducing a
new NcoI cloning site. Next, the 619 bp P97 ciliary
adhesin gene promoter sequence was amplified from
M. hyopneumoniae strain 232 [27] genomic DNA with
NcoI and NdeI restriction sites added (primers P97-1 and
P97-2). The P97 promoter sequence was then cloned into
the NcoI and NdeI restriction sites upstream of the Himar1
transposase gene, placing Himar1 under its control, and
completing plasmid pMHWT-1. To generate plasmid
pMHC9-1 (Figure 1E), the 1050 bp hyperactive C9
transposase mutant of Himar1 was PCR amplified from
plasmid pET29b + C9 [28], adding XhoI and NcoI restric-
tion sites (primers Tpn1 and Tpn2). This PCR product
was used to replace the wild-type Himar1 transposase gene
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of pMHWT-1, generating plasmid pMHC9-1 [GenBank
accession number KF861545] such that the C9 mutant
Himar1 is under control of the P97 promoter sequence.
Bacterial culture
M. hyopneumoniae strain 232 [27] was grown in Friis broth
medium at 37 °C in a static incubator [29]. For growth on
solid medium, Friis medium was solidified by addition of
0.8% w/v purified agar (Oxoid Ltd, Basingstoke, UK) and
0.01% w/v DEAE-dextran (Sigma-Aldrich Ltd, Gillingham,
UK) and incubated at 37 °C with 5% CO2. For the selection
of transformants, tetracycline hydrochloride (Sigma-Aldrich
Ltd, Gillingham, UK) was added to Friis broth medium and
Friis agar medium at final concentrations of 0.5 μg/mL and
0.2 μg/mL respectively. Molecular cloning was performed
using Escherichia coli strain DH5α, grown in Luria-Bertani
Table 1 Sequences of oligonucleotides.
Oligonucleotide Restriction sites Oligonucleotide sequence (5’-3’)
TetM1 PstI GCCGCTGCAGAATTAAAAGTTAGTG
TetM2 XbaI GAAATCTAGATTATATAACAACTTAAATTAC
TetM3 SbfI CGATCCTGCAGGCAGAATTAAAAGTTAGTG
TetM4 MluI CAGTACGCGTTTATATAACAACTTAAATTAC
Tpn1 NdeI/NcoI GCGCATATGCCATGGAAAAAAAGGAATTTCGTG
Tpn2 XhoI CGCCACTCGAGATTATTCAACATAGTTCCCTTC
P97-1 NdeI CGATCATATGACGGGGATTTAAAACAGAAAC
P97-2 NcoI GAATCCATGGCACCAACAATTCCGGCAGTC
TetMF N/A GTGGACAAAGGTACAACGAG
TetMR N/A CGGTAAAGTTCGTCACACAC
Linker-A N/A CGACTGGACCTGGA
Linker-B N/A GATAAGCAGGGATCGGAACCTCCAGGTCCAGTCG
L-PCR-C N/A GATAAGCAGGGATCGGAACC
L-PCR-L N/A GATAGGGTTGAGTGTTGTTC
L-PCR-R N/A TAGTCGGATAGATAAAGTAC
Sequences of oligonucleotides used in the study are shown. Where appropriate, the restriction enzyme recognition sites added to the 5’ end of the oligonucleotides
are underlined.
Figure 1 Plasmid maps and construction. Plasmid pTn4001-RVC1 was constructed by replacing the pac gene of pMiniTn4001PsPuro with tetM
from plasmid pSRT2 (A). Plasmid pMiniHimar1BSC1 contains a mini transposon incorporating pac conferring resistance to puromycin and the
wild-type Himar1 transposase downstream of the Tn4001 native promoter sequence (B) [26]. In the pMHWT-2 plasmid, the pac in pMiniHimar1BSC1
has been replaced with tetM from pSRT2 (C). In plasmid pMHWT-1, the promoter sequence of the M. hyopneumoniae strain 232 P97 gene has been
placed upstream of the wild-type Himar1 gene (D). In pMHC9-1, the wild-type Himar1 gene has been replaced with the hyperactive C9 mutant version
of the gene (E) [28].
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medium according to standard methods [30]. Transfor-
mants were selected by the addition of 100 μg/mL ampicil-
lin (Sigma-Aldrich Ltd, Gillingham, UK) to the medium.
Additionally, for the selection of transformants containing
the tetM gene, tetracycline hydrochloride was added to a
final concentration of 5 μg/mL.
Transformation of mycoplasmas
M. hyopneumoniae strain 232 was grown to mid-late
logarithmic phase in Friis broth as determined by an
acid colour change in the phenol red pH indicator.
Mycoplasmas were harvested by centrifugation of culture
at 9000 × g for 10 min at 4 °C and washed three times in
electroporation buffer (272 mM sucrose, 8 mM HEPES,
pH 7.4). One hundred microliters of cells (corresponding
to 3 mL culture) were incubated on ice with approxi-
mately 10 μg plasmid DNA for 30 min. Electroporation
was performed in a 0.2 cm cuvette (Bio-Rad Ltd, Hemel
Hempstead, UK) at 2.5 kV, 100 Ω, 25 μF and 900 μL ice-
cold Friis medium were immediately added. After 15 min
incubation on ice, cells were transferred to a 1.5 mL tube
and incubated at 37 °C for 3 h. Culture was then plated
onto Friis agar containing tetracycline and incubated at
37 °C in 5% CO2 for up to 18 days. Individual tetracycline-
resistant transformants were picked using a sterile pipette
tip into Friis broth medium containing tetracycline and
grown for 5–7 days until evidence of growth as determined
by the pH indicator.
Determination of transposon insertion sites
Transposon insertion site determination was based on
the method described by Chaudhuri et al. [31]. Genomic
DNA was extracted from M. hyopneumoniae strain 232
culture using a phenol-chloroform method [32]. Pres-
ence of tetM and plasmid backbone was determined by
PCR using primer pairs TetMF/TetMR and Tpn1/Tpn2
respectively. Two and a half micrograms of DNA were
digested overnight at 37 °C with 10 units of AluI, which
cuts the 892 kbp genome of M. hyopneumoniae strain
232 a total of 2239 times and generates blunt ends. AluI
also cuts within the tetM transposon sequence six times.
The digested DNA was purified using a MinElute PCR
Purification kit (Qiagen Ltd, Manchester, UK). Oligo-
nucleotide linkers were attached to the digested DNA
fragments. To generate the linker, 10 μM oligonucleotides
Linker-A and Linker-B (Table 1) were heated together
in a boiling water bath for 3 min in annealing buffer
(10 mM Tris–HCl, 50 mM NaCl, 1 mM EDTA, pH 8.0)
and then allowed to cool for 1 h at room temperature.
Fifty nanograms of AluI digested DNA were blunt-
ligated to 4 μL annealed oligonucleotides Linker-A and
Linker-B in a 10 μL reaction using a Quick Ligation kit
(NEB Ltd, Hitchin, UK) for 1 h at room temperature.
The ligated DNA was purified using a MinElute PCR
Purification kit (Qiagen Ltd, Manchester, UK). PCR was
performed using HotStarTaq (Qiagen Ltd, Manchester, UK)
according to the manufacturer’s instructions. Thermocycler
conditions were as follows: 95 °C for 15 min; 33 cycles of
94 °C for 45 s, 55 °C for 60 s, 72 °C for 120 s; 72 °C for
10 min. PCR products were visualised by electrophoresis in
1.6% agarose. Transposon insertion sites were determined
by the direct sequencing of PCR products.
Southern analysis
Southern blotting was performed based on previously
described methods [22]. Total DNA was extracted
from 20 mL mycoplasma broth culture using a phenol-
chloroform method [30,32] and 2.5 μg were digested to
completion with HindIII. DNA was separated by elec-
trophoresis on 0.9% agarose, blotted onto Hybond-N +
membrane (GE Healthcare Ltd, Little Chalfont, UK)
and then fixed to the membrane by exposure to UV
light. A digoxigenin (DIG)-labeled probe specific for
the tetM gene was generated from PCR-amplified DNA
(primers TetMF and TetMR, Table 1) using a DIG-
High Prime DNA Labelling and Detection Starter Kit
II (Roche Applied Science Ltd, Burgess Hill, UK). This
kit was also used to perform pre-hybridisation and hybrid-
isation in accordance with the manufacturer’s instruc-
tions. The membrane was autoradiographed at room
temperature using CL-XPosure Film (Fisher Scientific Ltd,
Loughborough, UK).
Results
Construction of transposon delivery vectors
Plasmid pTn4001-RVC1 (Figure 1A) was constructed
containing the Tn4001 transposase and a mini Tn4001
transposon consisting of the tetM gene under control of
the spiralin gene promoter sequence of Spiroplasma citri
bounded by inverted repeats. We previously optimised a set
of transformation conditions for M. hyopneumoniae using
an oriC-based self-replicating plasmid system, and showed
that tetM under control of the spiralin gene promoter
region was successfully expressed in M. hyopneumoniae
strain 232 allowing the selection of transformants on Friis
agar plates containing 0.2 μg/mL tetracycline [22]. How-
ever, despite three separate attempts at transforming M.
hyopneumoniae strain 232 with pTn4001-RVC using our
optimised conditions and our oriC plasmid pMHO-2 [22]
as a positive control for transformation, we obtained no
transformants. This suggested that the Tn4001 transposase
was not functional inM. hyopneumoniae.
A Himar1 transposon delivery vector (pMiniHimar1BSC1)
was recently described that successfully generated
transposon insertion mutants in the M. gallisepticum
R(low) strain and a small number of transposon insertions
in M. hyopneumoniae strain 232 [26]. pMiniHimar1BSC1
consists of the Himar1 transposase under control of the
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promoter sequence from Tn4001 and a transposon carrying
the pac gene conferring resistance to puromycin (Figure 1B).
Small numbers of mutants (less than 10 per transformation)
were generated in M. hyopneumoniae using this vector, but
transformation frequencies were very low and protracted
recovery times (several days) were required after transform-
ation prior to selection of transformants on solid medium.
We attempted to transform M. hyopneumoniae with
pMiniHimar1BSC1 and using a self-replicating oriC
plasmid (pMHOpuro) as a positive control for transform-
ation [22]. Approximately 106 CFU were transformed
with pMiniHimar1BSC1 and with pMHOpuro. On this
occasion, no puromycin resistant transformants were
generated with plasmid pMiniHimar1BSC1 while an
average of 1.5 × 10-4 transformants/CFU were produced by
the pMHOpuro positive control. To determine whether
tetM selection would increase the yield of transformants,
pac was replaced with tetM in plasmid pMHWT-2
(Figure 1C). An alternative hypothesis for the paucity
of transformants was that the Tn4001 promoter sequence
controlling Himar1 transposase expression was poorly
active in M. hyopneumoniae hence pMHWT-1 (Figure 1D)
was made by replacing the Tn4001 promoter sequence
regulating Himar1 with the P97 gene promoter of M.
hyopneumoniae strain 232 [22]. Plasmid pMHC9-1
(Figure 1E) was constructed by replacing the wild-type
Himar1 transposase with the C9 mutant form which
exhibits increased activity in vitro [28]. Additionally,
as a positive control for transformation, mycoplasmas
were transformed with the oriC-based plasmid pMHO-2
(containing tetM). Approximately 106 CFU were trans-
formed with pMHWT-2, pMHWT-1, pMHC9-1 and
pMHO-2 and selection plates examined after incubation
for 14 days. Plasmid pMHWT-2 failed to generate any
tetracycline resistant colonies compared to an average
of 4.6 × 10-5 transformants/CFU for the pMHO-2 positive
control Table 2. An average of 123 colonies per trans-
formation were found for pMHC9-1 containing the
hyperactive C9 mutant transposase compared to 33
colonies for pMHWT-1 containing the wild-type transpo-
sase. Transformation was repeated using pMHWT-1 and
pMHC9-1 but with approximately 108 CFU per transform-
ation. Again, more transformants were generated with the
hyperactive transposase (33 per transformation) compared
to the wild-type transposase (10 per transformation).
Transformation of an increased number of cells resulted in
a drop in the overall transformation efficiency. However,
our experiments suggested that the hyperactive C9 mutant
Himar1 transposase could account for a 3-4-fold increase
in transformation efficiency compared to the wild-type
transposase. Morphologically, tetracycline-resistant colonies
grown on Friis agar from transformed cells had a uniform
appearance that resembled that of colonies grown from
non-transformed cells (Figure 2). However, transformants
took approximately 3–5 days longer to reach the same
colony size as non-transformed cells. Transformed cells
formed discrete and well-separated colonies allowing the
isolation of individual colonies. Additionally, colonies were
relatively non-adherent to the agar surface and could be
easily removed by gentle washing with Friis medium. Im-
portantly, in none of the experiments described did we ob-
serve colonies in our “no DNA” control transformations,
indicating the absence of pseudo-resistance or spontaneous
resistance to tetracycline.
Analysis of transformants
Transformation of M. hyopneumoniae strain 232 with
plasmid pMHC9-1 consistently generated tetracycline
resistant colonies on Friis agar containing tetracycline. To
confirm that tetracycline resistance was due to transpos-
ition into the host chromosome and not, for example,
due to maintenance of extrachromosomal plasmid
DNA, 15 individual colonies from pMHC9-1 trans-
formed M. hyopneumoniae strain 232 were analysed.
Each was transferred into 1 mL Friis broth medium
containing 0.5 μg/mL tetracycline. All transformants
Table 2 Transformation frequencies using Himar1 constructs.
Plasmid Mean transformation frequency
(transformants/CFU) [SE]
Experiment 1 Experiment 2
pMHWT-2 0 NT
pMHWT-1 2.5 × 10-6 [1.3 × 10-6] 9.0 × 10-8 [2.4 × 10-8]
pMHC9-1 9.3 × 10-6 [4.5 × 10-6] 3.0 × 10-7 [4.6 × 10-8]
Mean transformation frequencies (with standard errors) are shown for three
separate transformations of M. hyopneumoniae strain 232 using plasmid
constructs pMHWT-1, pMHWT-2 and pMHC9-1 in two separate experiments. In
experiment 1, 106 CFU were transformed with each plasmid while in
experiment 2, 108 CFU were transformed.
Figure 2 Microscopic appearance of mutant M. hyopneumoniae
colonies. M. hyopneumoniae strain 232 was transformed with
plasmid pMHC9-1 and within 14 days, tetracycline resistant colonies
formed on Friis agar (A). No colonies were observed on “no DNA”
control transformations (B). Individual colonies exhibited a similar
appearance to non-transformed M. hyopneumoniae colonies. Tiny
deposits on the surface of the agar are typically seen and are considered
to arise from dead M. hyopneumoniae that have failed to grow in the
presence of tetracycline or from proteinaceous material in the fresh
yeast extract used (A and B).
Maglennon et al. Veterinary Research 2013, 44:124 Page 5 of 11
http://www.veterinaryresearch.org/content/44/1/124
grew within 5 days, confirming the maintenance of
tetracycline resistance upon sub-culturing into liquid
medium while no growth was observed for untrans-
formed controls. PCR amplification of tetM from total
DNA extracts prepared from 20 mL culture confirmed
the presence of tetM in all transformants generated
with the hyperactive C9 mutant transposase but not
un-transformedM. hyopneumoniae strain 232 (Figure 3A).
In addition, PCR for a region of the pUC19 plasmid back-
bone failed to amplify DNA for any transformant showing
that tetracycline resistance was not due to maintenance of
extrachromosomal plasmid DNA, or due to integration of
the entire plasmid, for example by homologous recombin-
ation at the P97 promoter sequence site (Figure 3B).
Analysis of transposon insertion sites
The presence of tetM and lack of plasmid backbone
suggested that transposition of the transposon into the
host chromosome had occurred. To locate the site of
transposition in randomly selected transformants, a
linker PCR technique was employed. Eleven individual
tetracycline resistant colonies were colony-purified on Friis
agar and cultured in Friis medium containing 0.5 ug/mL
tetracycline. PCR was used to amplify across the site of
insertion from the tetM to the linker. This was separ-
ately performed on DNA extracts using primer pairs to
recognise both ends of the transposon. Analysis showed
that a single dominant band was amplified for each
transformant using one of the oligonucleotide primer
pairs, consistent with integration of the transposon
into the host chromosome at one site only. Occasionally,
larger feint bands were also present, most likely due to
particular PCR parameters such as long extension times
and a high number of cycles, or by incomplete digestion
of chromosomal DNA by the restriction enzyme AluI. For
several transformants, no PCR product was obtained with
one of the two oligonucleotide primer pairs, but in all
cases, where one primer pair failed, a PCR product was
generated with the other primer pair. Therefore, it was
possible to confirm independent transposon insertions
for all of the 11 transformants. Additionally, the stability of
transposon insertion sites following multiple serial passages
Figure 3 Analysis of mutant M. hyopneumoniae by PCR. M. hyopneumoniae strain 232 was transformed with pMHC9-1. PCR was performed
on extracted total DNA from 15 individual transformants (lanes 1–15) for identification of the tetM gene (A) and the pGEM-T plasmid backbone
(B). A further 11 transformants underwent a further two rounds of “colony purification”. Total DNA was extracted and linker PCR performed using
two primer pairs at either end of the transposon (left and right) (C). The same 11 transformants were passaged 15 times in Friis medium without
selection, and all subsequently retained their resistance to tetracycline. Linker PCR was repeated using the same two primer pairs (left and right).
Control samples for PCR reactions included: “no template” control (NT); untransformed M. hyopneumoniae strain 232 (NC); plasmid DNA
positive control (PC).
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of individual transformants in non-selective Friis medium
was determined. Following a total of 15 passages in Friis
medium containing no tetracycline all individual transfor-
mants retained their resistance to tetracycline upon subse-
quent culture in medium containing tetracycline. Linker
PCR was repeated for each individual transformant, and
agarose gel electrophoresis showed that the amplicons gen-
erated were identical in size to those obtained prior to serial
passaging. Direct DNA sequencing of PCR amplicons was
performed and this confirmed that the transposon had
inserted into the host cell chromosome between thymine
and adenine residues as expected. Where sequencing at
both ends of the transposon was possible, the transposon
insertion sites were found to match. Southern analysis was
performed on total DNA extracted from the same 11 trans-
formants to confirm that only single transposon insertions
were present. For 10 of the mutants, a single band was
present using a DNA probe specific for tetM contained
within the transposon (Figure 4). For mutant 1, a small in-
tense band was present along with a larger feint band. Only
one insertion site was identified for this transformant by
linker PCR and this insertion site was confirmed by DNA
sequencing. It is possible that two bands were generated by
Southern analysis by a failure to adequately digest the DNA
to completion with HindIII.
Insertion sites of transposon mutants
Insertion site sequencing of a further 33 individual transfor-
mants was performed so that the locations of a total of 44
transformants were mapped to the M. hyopneumoniae
strain 232 genome (Figure 5). Of these 44 transformants,
41 contained unique insertion sites (Table 3). Mutants 49,
68 and 161 all contained an insertion at the nucleotide
549968 in the M. hyopneumoniae strain 232 genome and
mutants 56 and 66 contained identical insertion sites
at nucleotide 574428. It was not possible to determine
whether these mutants arose from a single transposition
event or from multiple events at the same location.
Following electroporation, mycoplasmas are given 3 hours
to recover and express tetM in Friis broth without tetracyc-
line prior to plating onto Friis agar containing tetracycline.
It is possible that a single transposition event was able to
undergo several rounds of multiplication during this period.
In total, transposon insertions were present in 22 open
reading frames (ORFs) and 5 non-coding regions (NCRs).
For 5 ORFs, there was more than one transformant
containing an insertion. The average size of an ORF in the
M. hyopneumoniae genome is 388 amino acids (aa). All 5
of these ORFs were larger than 388 aa and it is therefore
possible that more than one transformant was generated
due to the larger size of these ORFs. However, a total of 11
transformants contained a transposon insertion in mhp447.
Although this ORF is particularly large at 3970 aa, repre-
senting 1.3% of the M. hyopneumoniae strain 232 genome,
it is likely that this represents a “hotspot” for transposon
insertions. Similarly, 4 transformants contained insertions
in the smaller pepF gene (608 aa) and this too may be
Figure 4 Southern analysis of mutantM. hyopneumoniae. Total DNA
was extracted from 11 individual transformants of M. hyopneumoniae 232
generated using plasmid pMHC9-1, and subjected to Southern analysis
using a probe specific for tetM. Single bands were generated for 10 of the
mutants suggesting single transposon insertion sites. Two separate bands
were present for mutant 1. No band was present for the untransformed
M. hyopneumoniae strain 232 negative control (NC) and an intense band
was present for the pMHC9-1 positive control (PC) as expected.
Figure 5 Mapping of transposon insertions sites to the
M. hyopneumoniae genome. Transposon insertion sites were
determined by linker PCR and sequencing of PCR products for 44
individual mutants. The location of these insertion sites in the
M. hyopneumoniae strain 232 genome is depicted by lines emanating
from the circular genome (drawn to scale). Thicker lines indicate the
presence of more than one insertion at a given location.
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Table 3 Transposon insertion sites of M. hyopneumoniae strain 232 mutants.
Mutant Transposon insertion location ORF disrupted Gene function
72 84920 Mhp069 Unknown
11 85345 Mhp069 Unknown
40 259306 Tig Trigger factor
159 275721 NCR Unknown
50B 284811 Mhp261 Unknown
4 299711 Mhp271 P97 ciliary adhesion
96 318725 P95 Outer membrane protein
165 318913 P95 Outer membrane protein
91 359210 Mhp313 Unknown
9 434381 Mhp366 Unknown
34 466299 ulaA PTS system ascorbate-specific transporter subunit IIC
37 522533 Mhp443 Unknown
54B 527019 Mhp445 Unknown
156 537514 Mhp446 Unknown
75 540819 Mhp447 Unknown
53B 541339 Mhp447 Unknown
102 542436 Mhp447 Unknown
90 542541 Mhp447 Unknown
1 544071 Mhp447 Unknown
78 544309 Mhp447 Unknown
24 544767 Mhp447 Unknown
5 545264 Mhp447 Unknown
68 549968 Mhp447 Unknown
49 549968 Mhp447 Unknown
161 549968 Mhp447 Unknown
52B 551617 NCR Unknown
13 552503 NCR Unknown
56 574428 NCR Unknown
66 574428 NCR Unknown
17 608509 Mhp490 PTS system fructose-specific transporter subunit IIABC
16 652232 pepF Oligoendopeptidase F
162 653224 pepF Oligoendopeptidase F
101 653333 pepF Oligoendopeptidase F
92 653430 pepF Oligoendopeptidase F
47 672237 Mhp535 Unknown
170 672318 Mhp536 Unknown
63 672979 Mhp537 Unknown
50 686279 Mhp542 Unknown
19 722926 ulaA PTS system ascorbate-specific transporter subunit IIC
2 759509 NCR Regulatory region of glpD
10 788260 Mhp630 Unknown
7 788457 Mhp630 Unknown
12 790862 Mhp631 Unknown
51B 856887 pepP xaa-pro aminopeptidase
The locations of transposon insertions within the M. hyopneumoniae strain 232 genome for 44 individual pMHC9-1 transformants are shown. The open reading
frame (ORF) or non-coding region (NCR) containing the insertion is shown and, where known, the function of the protein encoded.
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over-represented. Most of the transposon insertions
are in genes of unknown function but that appear to be
dispensable for axenic growth, or in NCRs. Of the in-
sertions in genes of known function, three were in the
P97 ciliary adhesin and the P95 outer membrane protein.
Insertions were found in 3 genes encoding phospotrans-
ferase system subunit proteins specific for fructose and
ascorbate and in the molecular chaperone Trigger Factor.
Several insertions were also identified in the pepF gene en-
coding oligoendopeptidase F and the pepP gene encoding
a proline aminopeptidase. These are two of a small num-
ber of proteases that may be associated with processing of
M. hyopneumoniae cell surface proteins [33].
Generation of a large pool of M. hyopneumoniae mutants
We sought to determine whether our pMHC9-1 transposon
delivery vector could be used to produce a large pool of ran-
dom mutants, sufficient to provide an adequate number of
“hits” in all of the non-essential genes ofM. hyopneumoniae.
A pool of at least 10 000 individual mutants would be
expected to give a very high probability of an insertion
into every one of the 692 protein coding sequences in the
M. hyopneumoniae 232 genome determined by Minion
et al. [27]. It was calculated that a pool of 10 000 individ-
uals would, on average, contain a mycoplasma cell with an
insertion every 89 bp, and that there would be 14.45 inser-
tions per coding sequence. From the Poisson distribution,
10 000 independent insertions would give a 99.99995%
probability of an insertion into each one of the 692 coding
sequences. 20 individual transformations were performed
using plasmid pMHC9-1 with approximately 106 CFU per
transformation. After 14 days growth at 37 °C on agar
plates containing tetracycline, colonies were counted and
harvested together in one large pool. A total of 11 759
colonies were counted across all 20 plates, represent-
ing an average transformation frequency of 3.4 × 10-4
transformants/CFU (standard error 5.3 × 10-5).
Discussion
The inability to efficiently genetically manipulate M.
hyopneumoniae has stood as a hurdle to advancements
in the understanding of the pathogenesis of enzootic
pneumonia in pigs. We recently reported the successful
transformation of M. hyopneumoniae using an artificial
plasmid system containing the origin of replication of
M. hyopneumoniae and an antimicrobial resistance
cassette, that was capable of self-replicating and main-
tenance in transformed bacteria [22]. We have used
this system to optimise a number of conditions required
for the successful transformation of M. hyopneumoniae
by electroporation with plasmid DNA. This knowledge
has now enabled the design and construction of a
transposon-based system for generating random mu-
tants in M. hyopneumoniae.
The Tn4001 transposon is effective in generating inser-
tional mutations in a number of different Mycoplasma
species [16,18,19,34] but even using our optimised
transformation conditions, we were unable to demon-
strate transposition in M. hyopneumoniae. A Himar1
transposon delivery vector that was shown to be active in
M. gallisepticum generated very low numbers of transfor-
mants in M. hyopneumoniae with a very restricted range of
unique insertion sites [26]. By using anM. hyopneumoniae
strain 232-specific promoter sequence to control the
Himar1 expression and switching the wild-type Himar1
transposase for a hyperactive mutant C9 form, the fre-
quency of transposition increased significantly. Analysis
of transformants confirmed that resistance to tetracycline
was due to a transposition event into the mycoplasma
genome and it appeared that transposition occurred at a
single site in each individual transformant. The transposon
insertions appeared to be stable over serial passages and
were maintained even in the absence of antimicrobial
selection. These features are desirable when the phenotypes
of mutants are studied in vitro, and particularly for in vivo
studies of pools of mutants by TraDIS or signature-tagged
mutagenesis. Additionally, we did not encounter any
“pseudoresistant” colonies in our “no DNA” control trans-
formations, which have been documented in transposon
mutagenesis systems described for other mycoplasmas
[16,26]. “Pseudoresistant” colonies can complicate the
isolation of true transformants.
In the course of this study, it was evident that there
were significant differences in the transformation fre-
quencies obtained using plasmid pMHC9-1. We suspect
that differences in transformation frequency can be par-
tially accounted for by variations in the number of cells
electroporated and/or the growth phase of the myco-
plasma culture used. It appeared that an increase in the
number of cells transformed did not necessarily result in
an increase in transformation frequency. However, even
where similar numbers of cells were electroporated,
there could be significant differences in transformation
frequencies, implying that other factors could be im-
portant. Growth of M. hyopneumoniae is assessed and
monitored by a simple change in the phenol red pH in-
dicator incorporated into the medium, owing to the
fact that turbidity is not generated. Thus pH can serve
as a rough guide for growth phase, but the actual number
of cells can only be estimated after plating the culture
out and allowing growth on agar medium for 5–7 days.
Additionally, complex and undefined medium is used
to grow M. hyopneumoniae, with 20% equine/porcine
serum and freshly prepared yeast extract contributing
to variations in batches of medium.
Transposon insertion sites were determined for a limited
number of individual transformants using a linker PCR
technique and direct sequencing of PCR products by
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Sanger sequencing. From our limited analysis, we found
transposon insertions in a number of M. hyopneumoniae
genes of both known and unknown function, and in non-
coding regions. We observed a clustering of transposon
insertions in mhp447, a large open-reading frame of un-
known function. The Himar1 transposon inserts at 5’-TA-3’
dinucleotides and we considered that the large number of
insertions may be due to an increase in AT content.
However, analysis of this ORF showed that the AT content
was not unusual at 0.681 compared to 0.714 for the entire
M. hyopneumoniae strain 232 genome. Alternatively, it is
possible that there are hotspots for Himar1 insertions
in the M. hyopneumoniae strain 232 genome, that may
be affected by factors such as DNA topology, as is the
case with other transposons, including Mariner elements
[35]. It is difficult to draw any conclusions from analysis
of such a small pool of mutants, but determination of the
insertion sites of a large pool of mutants by next gener-
ation sequencing would answer the question of whether
favoured insertion sites do occur. Using plasmid pMHC9-1,
we were able to produce a large pool of mutants. Over
10 000 colonies were generated through a number of trans-
formations that, given an even distribution should be ex-
pected to have a high probability of insertions into all of the
genes of M. hyopneumoniae. This pool of mutants may
prove a valuable tool in future studies ofM. hyopneumoniae
in allowing a list of minimal essential genes to be deter-
mined. Such a pool of mutants could also be subjected to
an in vivo screen for attenuated mutants using powerful
functional genomic techniques such as TraDIS.
A novel transposon delivery system has been generated
for M. hyopneumoniae, allowing for the first time the
production of large numbers of random transposon in-
sertion mutants. This system has been used to generate
mutants with random transposon insertions in individ-
ual M. hyopneumoniae protein coding and non-coding
sequences. It has also been used to generate a large
pool of over 10 000 transposon insertions. These mu-
tants are powerful tools in elucidating the functions of
M. hyopneumoniae genes, and in turn unraveling the
pathogenesis of this important swine pathogen.
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